RU2762939C2 - Конъюгированные с лизином иммуноглобулины - Google Patents

Конъюгированные с лизином иммуноглобулины Download PDF

Info

Publication number
RU2762939C2
RU2762939C2 RU2018145507A RU2018145507A RU2762939C2 RU 2762939 C2 RU2762939 C2 RU 2762939C2 RU 2018145507 A RU2018145507 A RU 2018145507A RU 2018145507 A RU2018145507 A RU 2018145507A RU 2762939 C2 RU2762939 C2 RU 2762939C2
Authority
RU
Russia
Prior art keywords
immunoglobulin
amino acid
residue
acid residue
antigen
Prior art date
Application number
RU2018145507A
Other languages
English (en)
Russian (ru)
Other versions
RU2018145507A (ru
RU2018145507A3 (https=
Inventor
Джаред Спайдел
Эрл АЛБОН
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59315675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2762939(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of RU2018145507A publication Critical patent/RU2018145507A/ru
Publication of RU2018145507A3 publication Critical patent/RU2018145507A3/ru
Application granted granted Critical
Publication of RU2762939C2 publication Critical patent/RU2762939C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018145507A 2016-06-10 2017-06-12 Конъюгированные с лизином иммуноглобулины RU2762939C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348410P 2016-06-10 2016-06-10
US62/348,410 2016-06-10
PCT/JP2017/021672 WO2017213267A1 (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021136863A Division RU2021136863A (ru) 2016-06-10 2017-06-12 Конъюгированные с лизином иммуноглобулины

Publications (3)

Publication Number Publication Date
RU2018145507A RU2018145507A (ru) 2020-07-10
RU2018145507A3 RU2018145507A3 (https=) 2020-10-15
RU2762939C2 true RU2762939C2 (ru) 2021-12-24

Family

ID=59315675

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018145507A RU2762939C2 (ru) 2016-06-10 2017-06-12 Конъюгированные с лизином иммуноглобулины
RU2021136863A RU2021136863A (ru) 2016-06-10 2017-06-12 Конъюгированные с лизином иммуноглобулины

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021136863A RU2021136863A (ru) 2016-06-10 2017-06-12 Конъюгированные с лизином иммуноглобулины

Country Status (21)

Country Link
US (2) US10941431B2 (https=)
EP (1) EP3468614A1 (https=)
JP (1) JP7041077B2 (https=)
KR (1) KR102538866B1 (https=)
CN (1) CN109475642B (https=)
AU (1) AU2017279352B2 (https=)
BR (1) BR112018075253A2 (https=)
CA (1) CA3026991A1 (https=)
CL (1) CL2021003383A1 (https=)
CO (1) CO2018013314A2 (https=)
IL (1) IL263329B (https=)
JO (1) JOP20180118A1 (https=)
MX (1) MX419566B (https=)
MY (1) MY202858A (https=)
NZ (1) NZ748605A (https=)
PE (1) PE20190340A1 (https=)
PH (1) PH12018502594A1 (https=)
RU (2) RU2762939C2 (https=)
SG (1) SG11201810470XA (https=)
UA (1) UA126799C2 (https=)
WO (1) WO2017213267A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135304B2 (en) 2015-12-18 2021-10-05 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
UA126799C2 (uk) 2016-06-10 2023-02-08 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Кон'югований імуноглобулін
US20210054049A1 (en) * 2019-05-09 2021-02-25 Merus N.V. Variant domains for multimerizing proteins and separation thereof
GB201907093D0 (en) * 2019-05-20 2019-07-03 Ucl Business Plc Antibody functionalisation
CN115335406B (zh) * 2020-02-12 2026-01-30 伊莱利利公司 抗体或抗原-结合片段的结晶
EP4126929A1 (en) * 2020-03-25 2023-02-08 Eli Lilly and Company Multispecific binding proteins and methods of developing the same
WO2021234593A1 (en) 2020-05-20 2021-11-25 Janssen Biotech, Inc. Methods for site specific conjugation of proteins containing glycosylated fc domains
WO2022067076A1 (en) * 2020-09-25 2022-03-31 Epivax, Inc. Retro-inverso regulatory t cell epitopes
MX2024002476A (es) * 2021-08-27 2024-05-20 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos.
CN115947830B (zh) * 2022-12-27 2023-09-12 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
WO2024182569A2 (en) 2023-02-28 2024-09-06 Eisai R&D Management Co., Ltd. Anti-psma antibodies, conjugates, and methods of use
WO2024211135A2 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
WO2025020905A1 (zh) * 2023-07-26 2025-01-30 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
WO2026044149A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates
WO2026044039A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Anti-cd73 antibodies, conjugates, and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2385879C2 (ru) * 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
US20130230543A1 (en) * 2010-11-05 2013-09-05 Jaume Pons Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US20150017192A1 (en) * 2013-07-11 2015-01-15 Aimee Usera Site-specific chemoenzymatic protein modifications
WO2015015448A2 (en) * 2013-07-31 2015-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates
WO2015162563A1 (en) * 2014-04-25 2015-10-29 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
WO2013176516A1 (ko) 2012-05-24 2013-11-28 한화케미칼 주식회사 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
JP6744212B2 (ja) * 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
US11135304B2 (en) 2015-12-18 2021-10-05 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
UA126799C2 (uk) 2016-06-10 2023-02-08 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Кон'югований імуноглобулін

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2385879C2 (ru) * 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
US20130230543A1 (en) * 2010-11-05 2013-09-05 Jaume Pons Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US20150017192A1 (en) * 2013-07-11 2015-01-15 Aimee Usera Site-specific chemoenzymatic protein modifications
WO2015015448A2 (en) * 2013-07-31 2015-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates
WO2015162563A1 (en) * 2014-04-25 2015-10-29 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DENNLER P. et al.: Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates, BIOCONJUGATE CHEM. 2014, v.25, n.3, p.569-578. *
DENNLER P. et al.: Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates, BIOCONJUGATE CHEM. 2014, v.25, n.3, p.569-578. MINDT T.L. et al.: Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase, BIOCONJUGATE CHEM. 2008, v.19, n.1, p.271-278. JOSTEN A. et al.: Use of microbial transglutaminase for the enzymatic biotinylation of antibodies, JOURNAL OF IMMUNOLOGICAL METH., 2000, v.240, n.1-2, p.47-54. DEONARAIN M.L. et al.: Emerging formats for next-generation antibody drug conjugates, EXPERT OPIN DRUG DISCOV., 2015, v.10, n.5, p.463-481. *
DEONARAIN M.L. et al.: Emerging formats for next-generation antibody drug conjugates, EXPERT OPIN DRUG DISCOV., 2015, v.10, n.5, p.463-481. *
JOSTEN A. et al.: Use of microbial transglutaminase for the enzymatic biotinylation of antibodies, JOURNAL OF IMMUNOLOGICAL METH., 2000, v.240, n.1-2, p.47-54. *
MINDT T.L. et al.: Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase, BIOCONJUGATE CHEM. 2008, v.19, n.1, p.271-278. *

Also Published As

Publication number Publication date
NZ748605A (en) 2023-05-26
SG11201810470XA (en) 2018-12-28
AU2017279352B2 (en) 2024-07-25
RU2021136863A (ru) 2022-02-01
KR20190018159A (ko) 2019-02-21
US20180044711A1 (en) 2018-02-15
JP2019525897A (ja) 2019-09-12
EP3468614A1 (en) 2019-04-17
CN109475642A (zh) 2019-03-15
PE20190340A1 (es) 2019-03-07
MX419566B (es) 2025-01-14
CO2018013314A2 (es) 2019-02-19
IL263329A (en) 2018-12-31
MX2018015331A (es) 2019-08-16
JOP20180118A1 (ar) 2019-01-30
CN109475642B (zh) 2023-05-02
PH12018502594A1 (en) 2019-10-14
US10941431B2 (en) 2021-03-09
BR112018075253A2 (pt) 2019-04-30
JP7041077B2 (ja) 2022-03-23
CA3026991A1 (en) 2017-12-14
IL263329B (en) 2022-05-01
WO2017213267A1 (en) 2017-12-14
RU2018145507A (ru) 2020-07-10
MY202858A (en) 2024-05-25
RU2018145507A3 (https=) 2020-10-15
US11753669B2 (en) 2023-09-12
UA126799C2 (uk) 2023-02-08
AU2017279352A1 (en) 2018-12-13
KR102538866B1 (ko) 2023-06-02
CL2021003383A1 (es) 2022-08-19
US20210171998A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
RU2762939C2 (ru) Конъюгированные с лизином иммуноглобулины
US12214050B2 (en) C-terminal lysine conjugated immunoglobulins
CN113227124B (zh) 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
EP3795591B1 (en) Cys80 conjugated immunoglobulins
CA3008645C (en) C-terminal lysine conjugated immunoglobulins
WO2025093562A1 (en) Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
AU2022269007A1 (en) Methods and compositions thereof for site-specific labeling of human igg by proximity-based sortase-mediated ligation
HK40046837A (en) Cys80 conjugated immunoglobulins
HK1252625B (en) Cys80 conjugated immunoglobulins